Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Female Reproductive System Neoplasm
Platinum-Resistant Malignant Female Reproductive System Neoplasm
Recurrent Malignant Female Reproductive System Neoplasm
Refractory Malignant Female Reproductive System Neoplasm

Interventions

BIOLOGICAL: Durvalumab
RADIATION: Internal Radiation Therapy
BIOLOGICAL: Tremelimumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]